Related Experiment Video
Updated: Jun 3, 2026
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Improved cardiac function after sarcoplasmic reticulum Ca(2+)-ATPase gene transfer in a heart failure model induced
Wei Xin1, Xiaoying Li, Xiaochun Lu
1First Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China.
Insights
Gene transfer of sarco-endoplasmic reticulum calcium ATPase (SERCA2a) improved cardiac function in a chronic myocardial ischemia heart failure model. This suggests SERCA2a gene therapy is a promising treatment for heart failure related to CMI.
Area of Science:
- Cardiology
- Gene Therapy
- Heart Failure Research
Background:
- Chronic myocardial ischemia (CMI) is a significant contributor to heart failure (HF).
- Effective therapeutic strategies for CMI-induced HF remain a critical clinical challenge.
- Understanding molecular mechanisms underlying cardiac dysfunction in CMI is essential.
Purpose of the Study:
- To investigate the therapeutic potential of sarco-endoplasmic reticulum calcium ATPase (SERCA2a) gene transfer.
- To evaluate SERCA2a gene therapy in a large animal model of heart failure induced by chronic myocardial ischemia.
- To assess the impact of SERCA2a restoration on cardiac function and related biomarkers.
Main Methods:
- Heart failure was induced in mini pigs using left anterior descending coronary artery ameroid constrictors.
- Animals were divided into four groups: HF, HF+EGFP, HF+SERCA2a, and sham controls.
- Adeno-associated virus vectors (rAAV1-EGFP and rAAV1-SERCA2a) were administered intramyocardially.
Main Results:
- SERCA2a protein expression was significantly increased in the HF+SERCA2a group 60 days post-gene transfer.
- Left ventricular ejection fraction (LVEF), E/A ratio, and maximal first derivative of left ventricular pressure (+/- dp/dtmax) significantly improved in the HF+SERCA2a group.
- Serum levels of inflammatory and neuro-hormonal factors were reduced in the HF+SERCA2a group compared to controls.
Conclusions:
- Restoration of SERCA2a via gene transfer significantly enhances cardiac function in a CMI-induced HF model.
- SERCA2a gene therapy demonstrates considerable therapeutic promise for heart failure associated with chronic myocardial ischemia.
- This study supports the potential clinical application of SERCA2a gene therapy in managing CMI-related heart failure.
Objective:
Chronic myocardial ischaemia (CMI) has become an important cause of heart failure (HF). The aim of this study was to examine the effects of sarco-endoplasmic reticulum calcium ATPase (SERCA2a) gene transfer in large HF animal models induced by CMI.
Methods And Results:
HF was induced in mini pigs by proximal left anterior descending coronary (LAD) ameroid constrictors. After confirmation of myocardial perfusion defects and cardiac function impairment, animals were divided into 4 groups (each including 4 animals): the HF group; the HF+enhanced green fluorescent protein (EGFP) group; the HF+SERCA2a group; and sham animals as a control group, rAAV1-EGFP and rAAV1-SERCA2a were injected intramyocardially to animals of the HF+EGFP and HF+SERCA2a groups separately. Sixty days after gene transfer, expressions of SERCA2a were examined, cardiac functions and changes of serum inflammatory and neuro-hormonal factors were determined. The results demonstrated that 60 days after gene transfer, LVEF, Ev/Av and +/- dp/dtmax of the HF+SERCA2a group increased significantly (P < 0.05), along with an increase in SERCA2a protein expression (P < 0.05) compared with the HF/HF+EGFP groups. Serum concentrations of inflammatory and neuro-hormonal factors were also decreased in the HF+SERCA2a group (P < 0.05).
Conclusions:
Restoration of SERCA2a in myocardium of HF model induced by CMI could significantly improve cardiac function, suggesting its potential therapeutic significance in CMI-related heart failure.
